In this issue:
- Upfront ivonescimab vs. tislelizumab (+ chemotherapy) for advanced squamous NSCLC
- Trastuzumab deruxtecan in HER2-low metastatic breast cancer
- Perioperative nivolumab ± ipilimumab in resectable diffuse pleural mesothelioma
- Enfortumab vedotin + pembrolizumab for locally advanced/metastatic urothelial carcinoma
- Trastuzumab deruxtecan retreatment after recovery from grade 1 ILD
- Immunotherapy after acquired resistance with chemoimmunotherapy in unresectable biliary tract cancer
- Perioperative chemotherapy ± pembrolizumab in locally advanced gastric/gastro-oesophageal junction cancer
- Nivolumab-ipilimumab for metastatic castration-resistant prostate cancer with immunogenic signature
- Dual ICIs in newly diagnosed MGMT-unmethylated glioblastoma
Please login below to download this issue (PDF)